07:22 AM EST, 12/11/2024 (MT Newswires) -- Bausch+Lomb , a global eye health company, was at last look down 10% in US premarket trade on Wednesday -- after announcing that an affiliate acquired Elios Vision for an undisclosed sum.

A statement noted Elios Vision is developer of the 'ELIOS' procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser.

It said the acquisition "unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants" and "bolsters" Bausch + Lomb's ( BLCO ) glaucoma portfolio, which features pharmaceutical and surgical approaches.